Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci

American Journal of Epidemiology

Volumn 184, Issue 8, 2016, Pages 555-569

  Clyde, Merlise A ^a   Palmieri Weber, Rachel ^a   Iversen, Edwin S ^a   Poole, Elizabeth M ^a   Doherty, Jennifer A ^a   Goodman, Marc T ^a   Ness, Roberta B ^a   Risch, Harvey A ^a   Rossing, Mary Anne ^a   Terry, Kathryn L ^a   Wentzensen, Nicolas ^a   Whittemore, Alice S ^a   Anton Culver, Hoda ^a   Bandera, Elisa V ^a   Berchuck, Andrew ^a   Carney, Michael E ^a   Cramer, Daniel W ^a   Cunningham, Julie M ^a   Cushing Haugen, Kara L ^a   Edwards, Robert P ^a   Fridley, Brooke L ^a   Goode, Ellen L ^a   Lurie, Galina ^a   McGuire, Valerie ^a   Modugno, Francesmary ^a   Moysich, Kirsten B ^a   Olson, Sara H ^a   Pearce, Celeste Leigh ^a   Pike, Malcolm C ^a   Rothstein, Joseph H ^a   Sellers, Thomas A ^a   Sieh, Weiva ^a   Stram, Daniel ^a   Thompson, Pamela J ^a   Vierkant, Robert A ^a   Wicklund, Kristine G ^a   Wu, Anna H ^a   Ziogas, Argyrios ^a   Tworoger, Shelley S ^a   Schildkraut, Joellen M ^a   more..

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Genetic risk polymorphisms; model evaluation; ovarian cancer; risk model

Indexed keywords

AGE; BASELINE SURVEY; CANCER; DATA SET; EPIDEMIC; EPIDEMIOLOGY; GENETIC ANALYSIS; GENOME; POLYMORPHISM; PREDICTION; RISK ASSESSMENT; TUMOR;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; EVALUATION STUDY; FEMALE; GENE LOCUS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CARCINOMA; PREDICTIVE VALUE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

UNITED STATES;

EID: 84994152183     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kww091     Document Type: Article

References (66)

1. American Cancer Society. Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015. http://www. cancer. org/acs/groups/content/@editorial/documents/document/acspc-044552. pdf. Accessed September 14, 2016.
2. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
3. Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005;97(10):715-723.
4. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet. 2008;371(9609): 303-314.
5. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994; 344(8932):1250-1254.
6. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res. 2012;5(1):13.
7. Sieh W, Salvador S, McGuire V, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol. 2013;42(2):579-589.
8. Schildkraut JM, Risch N, Thompson WD. Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. Am J Hum Genet. 1989;45(4):521-529.
9. Beral V, Bull D, et al. Million Women Study Collaborators, Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369(9574):1703-1710.
10. Coughlin SS, Giustozzi A, Smith SJ, et al. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol. 2000;53(4):367-375.
11. Gong TT, Wu QJ, Vogtmann E, et al. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer. 2013;132(12):2894-2900.
12. Luan NN, Wu QJ, Gong TT, et al. Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. Am J Clin Nutr. 2013;98(4):1020-1031.
13. Pearce CL, Chung K, Pike MC, et al. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer. 2009;115(3): 531-539.
14. Rossing MA, Cushing-Haugen KL, Wicklund KG, et al. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(12): 2548-2556.
15. Trabert B, Wentzensen N, Yang HP, et al. Ovarian cancer and menopausal hormone therapy in the NIH-AARP Diet and Health Study. Br J Cancer. 2012;107(7):1181-1187.
16. Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol. 2008;108(3):641-651.
17. Trabert B, Ness RB, Lo-Ciganic WH, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014;106(2):djt431.
18. Heidemann LN, Hartwell D, Heidemann CH, et al. The relation between endometriosis and ovarian cancer-a review. Acta Obstet Gynecol Scand. 2014;93(1):20-31.
19. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385-394.
20. Andersen MR, Goff BA, Lowe KA, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116(3):378-383.
21. Collins GS, Altman DG. Identifying women with undetected ovarian cancer: independent and external validation of QCancer(® ) (Ovarian) prediction model. Eur J Cancer Care (Engl). 2013;22(4):423-429.
22. Hartge P, Whittemore AS, Itnyre J, et al. Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. Obstet Gynecol. 1994;84(5):760-764.
23. Pfeiffer RM, Park Y, Kreimer AR, et al. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med. 2013;10(7): e1001492.
24. Rosner BA, Colditz GA, Webb PM, et al. Mathematical models of ovarian cancer incidence. Epidemiology. 2005; 16(4):508-515.
25. Vitonis AF, Titus-Ernstoff L, Cramer DW. Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy. Obstet Gynecol. 2011;117(5): 1042-1050.
26. Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006;24(6):863-871.
27. Lee AJ, Cunningham AP, Kuchenbaecker KB, et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer. 2014;110(2):535-545.
28. Bojesen SE, Pooley KA, Johnatty SE, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013;45(4):371-384, 384e1-384e2.
29. Bolton KL, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010;42(10):880-884.
30. Goode EL, Chenevix-Trench G, Song H, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010; 42(10):874-879.
31. Permuth-Wey J, Lawrenson K, Shen HC, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21. 31. Nat Commun. 2013;4:1627.
32. Pharoah PD, Tsai YY, Ramus SJ, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013;45(4):362-370.
33. Song H, Ramus SJ, Tyrer J, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22. 2. Nat Genet. 2009;41(9):996-1000.
34. Kuchenbaecker KB, Ramus SJ, Tyrer J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015;47(2):164-171.
35. Bandera EV, King M, Chandran U, et al. Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. BMC Womens Health. 2011;11:40.
36. Kelemen LE, Sellers TA, Schildkraut JM, et al. Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Res. 2008;68(7):2498-2506.
37. Lo-Ciganic WH, Zgibor JC, Bunker CH, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology. 2012;23(2):311-319.
38. Lurie G, Wilkens LR, Thompson PJ, et al. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology. 2008;19(2):237-243.
39. McGuire V, Felberg A, Mills M, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol. 2004;160(7):613-618.
40. Pike MC, Pearce CL, Peters R, et al. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril. 2004;82(1):186-195.
41. Risch HA, Bale AE, Beck PA, et al. PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(9):1738-1741.
42. Schildkraut JM, Iversen ES, Wilson MA, et al. Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One. 2010;5(4):e10061.
43. Terry KL, De Vivo I, Titus-Ernstoff L, et al. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res. 2005;65(13): 5974-5981.
44. Wu AH, Pearce CL, Tseng CC, et al. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer. 2009;124(6):1409-1415.
45. Ziogas A, Gildea M, Cohen P, et al. Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(1):103-111.
46. Janes H, Pepe MS. Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting. Am J Epidemiol. 2008;168(1):89-97.
47. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. http://www. R-project. org/.
48. Wood SN. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models. J R Stat Soc Series B Stat Methodol. 2011; 73(1):3-36.
49. Wood SN. Generalized Additive Models: An Introduction with R. Boca Raton, FL: Chapman and Hall/CRC; 2006.
50. Moorman PG, Calingaert B, Palmieri RT, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol. 2008;167(9): 1059-1069.
51. Gelman A, Hill J. Data Analysis Using Regression and Multilevel/Hierarchical Models. Cambridge, New York: Cambridge University Press; 2007.
52. Little RJA, Rubin DB. Statistical Analysis With Missing Data. Hoboken, NJ: Wiley; 2002.
53. Plummer M. JAGS: A Program for Analysis of Bayesian Graphical Models Using Gibbs Sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003). Vienna, Austria, March 20-22, 2003.
54. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995;142(12):1255-1264.
55. Hoff PD. A First Course in Bayesian Statistical Methods. New York, NY: Springer; 2009.
56. Hüsing A, Canzian F, Beckmann L, et al. Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. J Med Genet. 2012;49(9):601-608.
57. Park JH, Gail MH, Greene MH, et al. Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers. J Clin Oncol. 2012;30(17):2157-2162.
58. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010;362(11):986-993.
59. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004; 159(9):882-890.
60. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst. 2008;100(14):1037-1041.
61. Darabi H, Czene K, Zhao W, et al. Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res. 2012;14(1):R25.
62. Mealiffe ME, Stokowski RP, Rhees BK, et al. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst. 2010; 102(21):1618-1627.
63. Pharoah PD, Antoniou AC, Easton DF, et al. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008;358(26):2796-2803.
64. Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst. 2009;101(13):959-963.
65. Tice JA, Cummings SR, Smith-Bindman R, et al. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148(5):337-347.
66. Tworoger SS, Zhang X, Eliassen AH, et al. Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. J Clin Oncol. 2014;56: 1068.